Seeking Alpha

Baird is defending Onyx Pharmaceuticals (ONXX -7.7%) mixed presentation yesterday at ASCO...

Baird is defending Onyx Pharmaceuticals (ONXX -7.7%) mixed presentation yesterday at ASCO yesterday, saying that any weakness in the stock would be buying opportunity. The company presented both positive and negative data for Kyprolis, but Baird thinks it could be a best-in-class protease inhibitor that will eventually gain approval. It maintains its Neutral rating, but raises its price target to $45 from $41.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)